核转染
TSG101型
妊娠期
反射减退
蛋白质基因组学
液化
食欲不振
心包积血
易熔合金
三醋酸甘油酯
渗滤
高乳酸血症
关节软骨损伤
肾小管病变
蛋白质异构体
杜瓦卢马布
作者
Lanlan Hu,Mingying Han,Jiaxin Yang,Yun Liu,Maoyu Qin,Jie Xu,Han Zhang,Xinyi Chen,Yinmu Li,Hong Meng,Sitian Liu,Yaobin Wu,Dingli Xu,Ling Wang
出处
期刊:Small
[Wiley]
日期:2025-05-26
卷期号:21 (30): e2505617-e2505617
标识
DOI:10.1002/smll.202505617
摘要
Abstract Advancing cardioprotective therapies requires physiologically relevant preclinical models, yet conventional approaches—including 2D cell cultures, 3D spheroids, and animal models—fail to fully recapitulate the structural complexity and dynamic microenvironment of native cardiac tissue, often facing species‐specific discrepancies and ethical concerns. Organ‐on‐a‐chip (OoC) technology, a microfluidic‐based biomimetic system, offers real‐time organ‐level physiology and disease progression monitoring. In this study, a heart‐on‐a‐chip (HoC) platform is developed by integrating cardiobundles—engineered 3D cardiac tissues—with microfluidic technology. Using a fibrinogen‐Matrigel hydrogel system, aligned cardiobundles are fabricated that mimic the native myocardial architecture and function. The HoC system demonstrates enhanced cardiomyocyte differentiation, intercellular connectivity, calcium handling, and contractility. Furthermore, the effects of oxygen and nutrient circulation, as well as dynamic microenvironmental conditions, are systematically assessed on cardiobundle performance, highlighting the platform's physiological relevance. This biomimetic HoC represents a promising tool for drug screening, disease modeling, and personalised medicine, offering a physiologically relevant alternative to traditional cardiac models in preclinical research.
科研通智能强力驱动
Strongly Powered by AbleSci AI